ID   SET-2
AC   CVCL_2187
SY   Set-2; Set2; SET2
DR   BTO; BTO:0004766
DR   EFO; EFO_0006486
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioGRID_ORCS_Cell_line; 804
DR   BioSample; SAMN03473274
DR   BioSample; SAMN10988088
DR   cancercelllines; CVCL_2187
DR   Cell_Model_Passport; SIDM00397
DR   ChEMBL-Cells; CHEMBL4523535
DR   ChEMBL-Targets; CHEMBL4523566
DR   Cosmic; 1012054
DR   Cosmic; 1519162
DR   Cosmic; 1633513
DR   Cosmic; 1943610
DR   Cosmic; 2306995
DR   Cosmic-CLP; 1659820
DR   DepMap; ACH-000195
DR   DSMZ; ACC-608
DR   DSMZCellDive; ACC-608
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GDSC; 1659820
DR   GEO; GSM887564
DR   GEO; GSM888647
DR   GEO; GSM1374868
DR   GEO; GSM1446764
DR   IARC_TP53; 28307
DR   LiGeA; CCLE_845
DR   Lonza; 1318
DR   PharmacoDB; Set2_1364_2019
DR   Progenetix; CVCL_2187
DR   PubChem_Cell_line; CVCL_2187
DR   Wikidata; Q54952857
RX   PubMed=10637490;
RX   PubMed=16408098;
RX   PubMed=22460905;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31739141;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Japanese.
CC   Doubling time: ~36 hours (PubMed=10637490); ~60-80 hours (DSMZ=ACC-608).
CC   HLA typing: A*02:01,33:03; B*40:02,44:03; C*03:03,14:03 (PubMed=26589293).
CC   HLA typing: A*02:01:01,33:03:01; B*40:02:01,44:03:01; C*03:03:01,14:03; DPA1*02:01:01,02:02:02; DPB1*09:01:01,05:01:01; DQA1*01:02:01,03:01:01; DQB1*03:02:01,06:09:01; DRA*01:01:01,01:02:02; DRB1*04:06:01,13:02:01 (DSMZCellDive=ACC-608).
CC   Sequence variation: Mutation; HGNC; 2978; DNMT3A; Simple; p.Arg882His (c.2645G>A); ClinVar=VCV000375881; Zygosity=Heterozygous (PubMed=31739141; DepMap).
CC   Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous (PubMed=16408098; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+2T>A; ClinVar=VCV000635391; Zygosity=Heterozygous; Note=Splice donor mutation (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=7.24%; Native American=0%; East Asian, North=78.39%; East Asian, South=9.7%; South Asian=0%; European, North=0%; European, South=4.67% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 8,10
ST   D16S539: 9,10
ST   D18S51: 13,16
ST   D19S433: 13
ST   D21S11: 30
ST   D2S1338: 18,23
ST   D3S1358: 14,16
ST   D5S818: 11
ST   D7S820: 10,12
ST   D8S1179: 13,14
ST   FGA: 19,23
ST   Penta D: 10,11 (DSMZ)
ST   Penta D: 11 (PubMed=25877200)
ST   Penta E: 16,20
ST   TH01: 7,9.3
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C7965; Adult acute megakaryoblastic leukemia
DI   ORDO; Orphanet_518; Acute megakaryoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   71Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 37
//
RX   PubMed=10637490; DOI=10.1038/sj.leu.2401608;
RA   Uozumi K., Otsuka M., Ohno N., Moriyama T., Suzuki S.,
RA   Shimotakahara S., Matsumura I., Hanada S., Arima T.;
RT   "Establishment and characterization of a new human megakaryoblastic
RT   cell line (SET-2) that spontaneously matures to megakaryocytes and
RT   produces platelet-like particles.";
RL   Leukemia 14:142-152(2000).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31739141; DOI=10.1016/j.leukres.2019.106270;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Fahnrich S., Hauer V.,
RA   Uphoff C.C., Zaborski M., Drexler H.G.;
RT   "DNMT3A R882H mutation in acute myeloid leukemia cell line SET-2.";
RL   Leuk. Res. 88:106270.1-106270.3(2020).
//